Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT06216678 Not yet recruiting - Clinical trials for Cardiovascular Diseases

The Effects of Healthy Diets With Plant Oils on Heart and Metabolic Health

Start date: May 2024
Phase: N/A
Study type: Interventional

This study will examine the effect of a healthy diet containing cottonseed oil compared to healthy diets containing other commonly consumed plant oils on biomarkers of heart and metabolic health after 4 weeks.

NCT ID: NCT06215911 Recruiting - Heart Failure Clinical Trials

A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)

Cycle-1-REF
Start date: February 13, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.

NCT ID: NCT06215586 Recruiting - Heart Failure Clinical Trials

Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

Cycle-2-PEF
Start date: February 13, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction

NCT ID: NCT06213714 Not yet recruiting - Clinical trials for Coronary Artery Disease

The 5th Generation Tele-Robotic-Assisted Percutaneous Coronary Intervention: A First-in-Human Trial

Start date: February 2024
Phase: N/A
Study type: Interventional

The objective of this study is to examine the safety and effectiveness, from both clinical and technical perspectives, of utilizing the 5G-Robotic VRS100 system in percutaneous coronary intervention (PCI).

NCT ID: NCT06211868 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study

RESET
Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.

NCT ID: NCT06211465 Completed - Clinical trials for Cardiovascular Diseases

Cardiovascular And Metabolic Risk After Arthroplasty

CAMERA
Start date: March 1, 2014
Phase:
Study type: Observational

Osteoarthritis is a chronic joint disease that lacks curative therapy. Epidemiological studies show increase in the burden of disease. Total joint arthroplasty is one of the best treatment options for end-stage osteoarthritis. However, the specific effects of total joint arthroplasty on cardiovascular risk and metabolic profile are largely unknown. The aim of this project is to elucidate how hip and knee total joint arthroplasty impacts cardiovascular risk and metabolomic profile in comparison with general population. We hypothesize that arthroplasty decreases pain, systemic inflammation levels and increases functional status that all lead to decreased metabolic and cardiovascular risk.

NCT ID: NCT06211361 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Cardiac Rehabilitation Program in Patients With Cardiovascular Disease

Start date: September 8, 2024
Phase: N/A
Study type: Interventional

This protocol study aims to evaluate the effectiveness of a cardiac rehabilitation intervention program in patients with cardiovascular diseases to improve both anthropometric and biochemical data, as well as other variables related to cardiovascular disorders (cardiorespiratory fitness, muscle strength, …), and emotional aspects (anxiety, depression). Additionally, this study aims to evaluate the effectiveness of the cardiac rehabilitation program in improving body composition (waist circumference and body fat percentage), blood pressure and health-related quality of life. Objectives: i) To assess the functional capacity of patients with a recent cardiovascular event (acute coronary syndrome, onset heart failure, valve or bypass surgery) or with chronic decompensated cardiovascular disease (valvulopathy, pulmonary hypertension, congenital heart disease, heart failure) chronic), ii) to determine the different cardiorespiratory parameters obtained from cardiopulmonary exercise testing (CPET), iii) to determine the lifestyle habits and cardiovascular risk factors, iv) to develop a cardiac rehabilitation program according to and adapted to the need of each of these patients, v) to estimate the effect of the intervention, both in the muscle strength and in post-intervention CPET, biochemical and anthropometric parameters, v) to estimate the effect of the intervention in the quality of life, anxiety, depression, and adherence to the Mediterranean diet.

NCT ID: NCT06204549 Recruiting - Clinical trials for Major Adverse Cardiac Events

Impact of Assessment and Management of Comorbidities in Internal Medicine on Cardiovascular Risk

COMMEDCARDIO
Start date: May 21, 2024
Phase: N/A
Study type: Interventional

The aim of assessing and managing cardiovascular risk is to avoid, limit or delay cardiovascular morbidity and mortality. Planned internal medicine hospitalization is developed around the management of cardiovascular risk in patients at high cardiovascular risk, whether in primary prevention or secondary prevention. During planned hospitalization, patients benefit from comprehensive, personalized and adapted care for their comorbidities and their CVRF (cardiovascular risk factors). This study will make it possible to evaluate this overall course of multidisciplinary management of comorbidities of patients at high cardiovascular risk.

NCT ID: NCT06203860 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

The Cardio-Metabolic Clinic

ProtecT-2-D
Start date: November 1, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate whether a Cardio-Metabolic Clinic can protect the cardiovascular health of patients with both diabetes and cardiovascular disease. - At the Cardio-Metabolic Clinic, patients will receive a specialized and comprehensive care. This includes applying a systematic approach, considering their whole health based on the latest knowledge in the field, and administering aggressive treatment with heart protective medications. - The ProtecT-2-D trial will compare the effects of care at the Cardio-Metabolic Clinic to usual care to see if there are any differences in cardiovascular illness and death.

NCT ID: NCT06202820 Not yet recruiting - Prostate Cancer Clinical Trials

CV CARE: CardioVascular Care in PC Patients

Start date: June 2024
Phase: N/A
Study type: Interventional

This research is being done to test a program to assess and manage reversible cardiovascular (CV) risk factors in participants with prostate cancer starting androgen deprivation therapy (ADT), with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants. The name of the intervention used in this research study is: CV Care (cardiovascular risk assessment and management program)